Dr. Skarbnik on the Approval of Brexucabtagene Autoleucel in MCL

Alan P. Z. Skarbnik, MD, discusses the approval of brexucabtagene autoleucel in ​relapsed/refractory mantle cell lymphoma.

Alan P. Z. Skarbnik, MD, a hematologist/oncologist with Novant Health, discusses the approval of brexucabtagene autoleucel (Tecartus) in ​relapsed/refractory mantle cell lymphoma (MCL).

On July 24, 2020, the FDA approved the CAR T-cell therapy brexucabtagene autoleucel for patients with ​relapsed/refractory MCL based on findings from the ​phase 2 ZUMA-2 study, says Skarbnik.

The ZUMA-2 trial evaluated brexucabtagene autoleucel in patients with relapsed/refractory MCL who previously received a BTK inhibitor​, Skarbnik says. Notably, the CAR T-cell product induced an 87% objective response rate and a 62% complete response rate in this patient population. 

​However, the regulatory decision does not require ​patients to have had prior exposure to a BTK inhibitor, ​explains Skarbnik.

Although BTK inhibitors offer an effective therapy for patients with relapsed/refractory MCL, the majority of responses do not exceed 26 months, Skarbnik explains.

As such, ​the decision to approve brexucabtagene autoleucel for all patients with relapsed/refractory MCL may allow more patients to derive extended responses, concludes Skarbnik.

Related Videos
Brian Henick, MD
Abhinav Deol, MD
Veronika Bachanova, MD, PhD
Walter M. Stadler, MD
Susan Domchek, MD, FASCO
Robert Dreicer, MD, director, Solid Tumor Oncology, Division of Hematology/Oncology, professor of Medicine and Urology, deputy director, University of Virginia Cancer Center
Amy L. Cummings, MD, thoracic oncologist, assistant professor of medicine, David Geffen School of Medicine, University of California Los Angeles (UCLA) Jonsson Comprehensive Cancer Center
Amandeep Godara, MBBS
Eunice Wang, MD
Yvonne Chao, MD, PhD
Related Content